Alvotech · NASDAQ (us_market)
Healthcare · Drug Manufacturers - Specialty & Generic · Luxembourg
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-12-11$5.75 RISE2026-03-27$3.11 PEAK2026-04-06$3.79 116d | -45.9% 106d | Missed | Missed | — | — | +21.9% 10d | Missed |
DROP2025-10-15$8.98 RISE2026-01-06$4.58 PEAK2026-01-29$5.42 106d | -49.0% 83d | Missed | Missed | — | — | +18.3% 23d | Missed |
DROP2025-07-28$9.81 RISE2025-12-02$4.60 PEAK2025-12-11$5.75 136d | -53.1% 127d | Missed | Missed | — | — | +25.0% 9d | Missed |
DROP2025-03-25$11.66 RISE2025-07-15$8.41 PEAK2025-07-28$9.81 125d | -27.9% 112d | Missed | Missed | — | — | +16.6% 13d | Missed |
DROP2025-01-10$13.52 RISE2025-04-30$7.84 PEAK2025-06-03$11.45 144d | -42.0% 110d | Missed | Missed | — | — | +46.0% 34d | Missed |
DROP2024-05-02$14.51 RISE2024-09-11$10.76 PEAK2024-10-25$13.08 176d | -25.8% 132d | Missed | Missed | — | — | +21.6% 44d | Missed |
DROP2024-02-26$17.27 RISE2024-04-02$11.40 PEAK2024-05-02$14.51 66d | -34.0% 36d | Missed | Missed | — | — | +27.3% 30d | Missed |
DROP2023-07-24$10.07 RISE2023-10-26$8.55 PEAK2024-01-23$14.25 183d | -15.1% 94d | Missed | Missed | — | — | +66.7% 89d | Missed |
DROP2023-03-02$14.03 RISE2023-06-29$6.90 PEAK2023-07-24$10.07 144d | -50.8% 119d | Missed | Missed | — | — | +45.9% 25d | Missed |
DROP2022-08-16$9.25 RISE2022-11-15$5.76 PEAK2023-02-10$13.39 178d | -37.7% 91d | Missed | Missed | — | — | +132.5% 87d | Missed |
DROP2022-06-16$11.19 RISE2022-07-15$5.53 PEAK2022-08-16$9.25 61d | -50.6% 29d | Missed | Missed | — | — | +67.3% 32d | Missed |
Alvotech (NASDAQ:ALVO) Chief Strategy Officer Balaji Prasad said the biosimilar developer is preparing to resubmit three biologics license applications to the U.S. Food and Drug Administration in June after addressing manufacturing observations that led to complete response letters for pipeline prod
Alvotech (NASDAQ:ALVO) Chief Strategy Officer Balaji Prasad said the biosimilar developer is preparing to resubmit three biologics license applications to the U.S. Food and Drug Administration in June after addressing manufacturing observations that led to complete response letters for pipeline prod
Alvotech (ALVO) Bank of America Global Healthcare Conference 2026 May 13, 2026 6:40 PM EDTCompany ParticipantsBalaji Prasad - Chief Strategy...
Presenter SpeechJason Gerberry Next company presenter at the BofA Annual Healthcare Conference. Jason Gerberry, pharma and biotech analyst. Pleased to be introducing Alvotech, and Balaji Prasad,
Alvotech announced that the U.S. Food and Drug Administration has completed a routine cGMP surveillance inspection of the company?s manufacturing facility in Reykjavik, Iceland. At the conclusion of...
Company remains on track for BLA resubmissions in the second quarter REYKJAVIK, ICELAND – May 11, 2026 – Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announces that the U.S. Food and Drug Administration (FDA) has completed a routine cGMP surveillance inspection of the company’s manufacturing facility in Reykjavik, Iceland. At the conclusion of the inspection on May 8, 2026,
Robert Wessman: Good morning, everyone, and thank you for joining us. The first quarter was focused on three priorities, progressing the FDA resubmission, maintaining a high level of inspection readiness and continuing to expand our commercial business globally, including the launch of three biosimilars across Europe and rest of the world markets. Last week, the FDA began a routine GMP surveillance inspection at our Reykjavik facility, which is currently ongoing.
Robert Wessman: Good morning, everyone, and thank you for joining us. The first quarter was focused on three priorities, progressing the FDA resubmission, maintaining a high level of inspection readiness and continuing to expand our commercial business globally, including the launch of three biosimilars across Europe and rest of the world markets. Last week, the FDA began a routine GMP surveillance inspection at our Reykjavik facility, which is currently ongoing.
Alvotech has reported past first-quarter 2026 earnings, with net income of US$1.03 million compared with US$109.68 million a year earlier, and confirmed the planned departure of long-serving General Counsel Tanya Zharov. The sharp year-on-year swing in net income and a leadership transition in the legal function together raise fresh questions about earnings quality, governance continuity and how the biosimilar pipeline is being supported. Next, we’ll examine how this sharp year-on-year net...
Alvotech has reported past first-quarter 2026 earnings, with net income of US$1.03 million compared with US$109.68 million a year earlier, and confirmed the planned departure of long-serving General Counsel Tanya Zharov. The sharp year-on-year swing in net income and a leadership transition in the legal function together raise fresh questions about earnings quality, governance continuity and how the biosimilar pipeline is being supported. Next, we’ll examine how this sharp year-on-year net...
Alvotech (ALVO) Q1 2026 Earnings Call May 7, 2026 8:00 AM EDTCompany ParticipantsBenedikt Stefansson - Vice President of Investor Relations & Global...
Presentation Operator MessageOperator Good day and thank you for standing by. Welcome to the Alvotech First Quarter 2026 Earnings Conference Call. [Operator Instructions] Please be advised that...
Alvotech (NASDAQ:ALVO) executives said the company’s first-quarter priorities centered on advancing U.S. regulatory work, maintaining inspection readiness, and expanding commercial activity globally as the biosimilar developer works through manufacturing enhancements at its Reykjavik facility. FDA
Alvotech (NASDAQ:ALVO) executives said the company’s first-quarter priorities centered on advancing U.S. regulatory work, maintaining inspection readiness, and expanding commercial activity globally as the biosimilar developer works through manufacturing enhancements at its Reykjavik facility. FDA
Alvotech (ALVO) delivered earnings and revenue surprises of -28.57% and -22.19%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Alvotech (ALVO) delivered earnings and revenue surprises of -28.57% and -22.19%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Alvotech Q1 2026 revenue and EPS missed analyst expectations, causing shares to dip over 9%. Despite the quarterly shortfall from a production slowdown, the company reaffirmed full-year guidance and advanced key pipeline milestones.
REYKJAVIK, Iceland, May 06, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ US: ALVO, ICELAND: ALVO, STOCKHOLM: ALVO SDB) Financial Highlights A supplemental long‑form earnings release providing additional operational details and business update for Q1 2026 is available at: https://investors.alvotech.com/earnings-calendar under “Q1 2026 Earnings Call”. The supplemental document is provided solely for reference and is not part of this SEC Form 6‑K. The Form 6‑K should not be read together with, or cons
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ALVO | -2.89% | -15.15% | -34.50% | -70.63% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -5.86% | -9.44% | -31.06% | -83.32% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| RenTech | quant | 63.2K | $216.78K | 0.00% | Added+146.9% | 2026-03-31 |
| TRowePrice | fundamental | 1.40M | $4.79K | 0.00% | Trimmed-2.6% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-19upcoming | — | — | — |
| 2026-05-05 | -0.07 | -0.09 | -28.57% |
| 2026-03-17 | -0.01 | 0.01 | +190.83% |
| 2025-11-13 | -0.03 | -0.11 | -230.93% |
| 2025-08-13 | — | 0.03 | +1410.04% |
| 2025-03-26 | -0.03 | -0.24 | -779.12% |
| 2024-11-13 | -0.06 | -0.48 | -661.90% |
| 2024-08-15 | — | 0.18 | +6000.00% |
| 2024-05-21 | -0.08 | -0.33 | -301.20% |
| 2024-03-20 | -0.07 | -1.22 | -1748.48% |
| 2023-11-28 | -0.07 | -0.82 | -1071.43% |